0001493152-19-018758.txt : 20191205 0001493152-19-018758.hdr.sgml : 20191205 20191204215400 ACCESSION NUMBER: 0001493152-19-018758 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20191205 DATE AS OF CHANGE: 20191204 EFFECTIVENESS DATE: 20191205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Protagenic Therapeutics, Inc.\new CENTRAL INDEX KEY: 0001022899 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 061390025 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-352091 FILM NUMBER: 191269373 BUSINESS ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: (212) 994-8200 MAIL ADDRESS: STREET 1: 149 FIFTH AVENUE STREET 2: SUITE 500 CITY: NEW YORK STATE: NY ZIP: 10010 FORMER COMPANY: FORMER CONFORMED NAME: Atrinsic, Inc. DATE OF NAME CHANGE: 20090630 FORMER COMPANY: FORMER CONFORMED NAME: NEW MOTION, INC. DATE OF NAME CHANGE: 20070504 FORMER COMPANY: FORMER CONFORMED NAME: MPLC, Inc. DATE OF NAME CHANGE: 20050608 D/A 1 primary_doc.xml X0708 D/A LIVE 0001022899 Protagenic Therapeutics, Inc.\new 149 FIFTH AVENUE, SUITE 500 NEW YORK NY NEW YORK 10010 212-994-8200 DELAWARE New Motion, Inc. Atrinsic, Inc. NEW MOTION, INC. MPLC, Inc. Corporation true Garo H Armen 149 Fifth Avenue, Suite 500 New York NY NEW YORK 10010 Executive Officer Director Robert B Stein 149 Fifth Avenue, Suite 500 New York NY NEW YORK 10010 Director Khalil Barrage 149 Fifth Avenue, Suite 500 New York NY NEW YORK 10010 Director Joshua Silverman 149 Fifth Avenue, Suite 500 New York NY NEW YORK 10010 Director Brian J Corvese 149 Fifth Avenue, Suite 500 New York NY NEW YORK 10010 Director Alexander K Arrow 149 Fifth Avenue, Suite 500 New York NY NEW YORK 10010 Executive Officer Biotechnology Decline to Disclose 06b true 0001493152-19-016091 2019-11-05 false true true false 0 Katalyst Securities LLC 112494 None None 15 MAIDEN LANE ROOM 601 NEW YORK NY NEW YORK 10038 All States false 2500000 555000 1945000 Includes $500,000 principal amount of convertible notes which may be sold in the event the offering is over-subscribed. false 10 16400 0 Placement Agent is entitled to receive 8% cash fees for all equity raised by the Placement Agent during the offering. Does not include warrants issuable to Placement Agent. 0 false Protagenic Therapeutics, Inc.\new /s/ Alexander K. Arrow Alexander K. Arrow Chief Financial Officer 2019-12-04